Literature DB >> 15166272

CDX-2 immunostaining in primary and secondary ovarian carcinomas.

L Tornillo1, H Moch, P-A Diener, A Lugli, G Singer.   

Abstract

AIMS: To assess the value of homeobox protein CDX-2 expression in the distinction between primary ovarian carcinomas and carcinomas metastatic to the ovary.
METHODS: CDX-2 expression was assessed by immunohistochemistry in 120 serous, 68 endometrioid, 24 clear cell, and 16 mucinous carcinomas of the ovary. In addition, CDX-2 immunoreactivity was investigated in 20 metastases from adenocarcinomas to the ovary (15 of colorectal, two of gastric, one of appendiceal, one of pancreatic, and one of cervical origin) and their corresponding primary tumours.
RESULTS: Almost all of the primary ovarian carcinomas lacked immunoreactivity for CDX-2. In contrast, 14 of the 16 metastases to the ovary from intestinal primaries showed CDX-2 immunoexpression.
CONCLUSION: CDX-2 is a useful marker for differentiating primary ovarian carcinoma from carcinomas metastatic to the ovary.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15166272      PMCID: PMC1770317          DOI: 10.1136/jcp.2003.013615

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  11 in total

1.  Tissue microarrays for rapid linking of molecular changes to clinical endpoints.

Authors:  J Torhorst; C Bucher; J Kononen; P Haas; M Zuber; O R Köchli; F Mross; H Dieterich; H Moch; M Mihatsch; O P Kallioniemi; G Sauter
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

2.  Expression of cytokeratins 7 and 20 in primary carcinomas of the stomach and colorectum and their value in the differential diagnosis of metastatic carcinomas to the ovary.

Authors:  So Yeon Park; Hee Sung Kim; Eun Kyung Hong; Woo Ho Kim
Journal:  Hum Pathol       Date:  2002-11       Impact factor: 3.466

3.  The distinction between primary and metastatic mucinous carcinomas of the ovary: gross and histologic findings in 50 cases.

Authors:  Kenneth R Lee; Robert H Young
Journal:  Am J Surg Pathol       Date:  2003-03       Impact factor: 6.394

4.  Combined array comparative genomic hybridization and tissue microarray analysis suggest PAK1 at 11q13.5-q14 as a critical oncogene target in ovarian carcinoma.

Authors:  Peter Schraml; Georg Schwerdtfeger; Felix Burkhalter; Anna Raggi; Dietmar Schmidt; Teresa Ruffalo; Walter King; Kim Wilber; Michael J Mihatsch; Holger Moch
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

5.  Intestinal adenocarcinomas metastatic to the ovaries. A clinicopathologic evaluation of 22 cases.

Authors:  R H Lash; W R Hart
Journal:  Am J Surg Pathol       Date:  1987-02       Impact factor: 6.394

6.  Differentiation of ovarian mucinous carcinoma and metastatic colorectal adenocarcinoma by immunostaining with beta-catenin.

Authors:  Y-Y Chou; Y-M Jeng; H-L Kao; T- J Chen; T-L Mao; M-C Lin
Journal:  Histopathology       Date:  2003-08       Impact factor: 5.087

7.  Cdx2 protein expression in normal and malignant human tissues: an immunohistochemical survey using tissue microarrays.

Authors:  Christopher A Moskaluk; Hong Zhang; Steven M Powell; Lisa A Cerilli; Garret M Hampton; Henry F Frierson
Journal:  Mod Pathol       Date:  2003-09       Impact factor: 7.842

8.  CDX-2 homeobox gene expression is a reliable marker of colorectal adenocarcinoma metastases to the lungs.

Authors:  M Barbareschi; B Murer; T V Colby; M Chilosi; E Macri; M Loda; C Doglioni
Journal:  Am J Surg Pathol       Date:  2003-02       Impact factor: 6.394

9.  Cytokeratins 7 and 20, Dpc4, and MUC5AC in the distinction of metastatic mucinous carcinomas in the ovary from primary ovarian mucinous tumors: Dpc4 assists in identifying metastatic pancreatic carcinomas.

Authors:  Hongxiu Ji; Christina Isacson; Jeffrey D Seidman; Robert J Kurman; Brigitte M Ronnett
Journal:  Int J Gynecol Pathol       Date:  2002-10       Impact factor: 2.762

10.  Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis.

Authors:  Jeffrey D Seidman; Robert J Kurman; Brigitte M Ronnett
Journal:  Am J Surg Pathol       Date:  2003-07       Impact factor: 6.394

View more
  6 in total

1.  CDX2 as a marker for intestinal differentiation: Its utility and limitations.

Authors:  Reda S Saad; Zeina Ghorab; Mahmoud A Khalifa; Mei Xu
Journal:  World J Gastrointest Surg       Date:  2011-11-27

Review 2.  Differentiating rectal carcinoma by an immunohistological analysis of carcinomas of pelvic organs based on the NCBI Literature Survey and the Human Protein Atlas database.

Authors:  Koh Miura; Kazuyuki Ishida; Wataru Fujibuchi; Akihiro Ito; Hitoshi Niikura; Hitoshi Ogawa; Iwao Sasaki
Journal:  Surg Today       Date:  2012-03-23       Impact factor: 2.549

3.  Low meprin alpha expression differentiates primary ovarian mucinous carcinoma from gastrointestinal cancers that commonly metastasise to the ovaries.

Authors:  Viola A Heinzelmann-Schwarz; Richard A Scolyer; James P Scurry; Alison N Smith; Margaret Gardiner-Garden; Andrew V Biankin; Sally Baron-Hay; Carolyn Scott; Robyn L Ward; Daniel Fink; Neville F Hacker; Robert L Sutherland; Philippa M O'Brien
Journal:  J Clin Pathol       Date:  2006-07-05       Impact factor: 3.411

4.  Clinicopathologic and immunohistochemical profile of ovarian metastases from colorectal carcinoma.

Authors:  Gozde Kir; Ayse Gurbuz; Ates Karateke; Mustafa Kir
Journal:  World J Gastrointest Surg       Date:  2010-04-27

5.  Dual Immunostain With SATB2 and CK20 Differentiates Appendiceal Mucinous Neoplasms From Ovarian Mucinous Neoplasms.

Authors:  Zaibo Li; Rachel Roth; Jonathan B Rock; Amy Lehman; William L Marsh; Adrian Suarez; Wendy L Frankel
Journal:  Am J Clin Pathol       Date:  2017-05-01       Impact factor: 2.493

6.  CDX2 immunostaining in primary and metastatic germ cell tumours of the testis.

Authors:  Fatma Oz Atalay; Berna Aytac Vuruskan; Hakan Vuruskan
Journal:  J Int Med Res       Date:  2016-11-11       Impact factor: 1.671

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.